Plain-English translation of NCT07590934 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether , a new type of targeted cancer therapy, works better when combined with another drug called palacaparib compared to receiving either treatment alone or standard chemotherapy. The study includes men with advanced prostate cancer that has spread to other parts of the body and has become resistant to hormone therapy. Researchers want to understand how safe this medication is and whether it can shrink tumors or slow cancer growth.
Men with advanced prostate cancer that no longer responds to hormone treatments have limited options, and current chemotherapy doesn't work for everyone. This medication represents a new approach designed to target specific cancer cells, and this trial will show whether combining it with another drug could offer a better outcome than treatments available today.
You likely qualify if…
You likely don't qualify if…
The trial has two main phases: first, doctors will test increasing doses of the medication combination to find the safest and most effective dose, then expand enrollment to confirm how well it works. Depending on which group you are assigned to, you will either take pills daily in combination with an injection every 6 weeks, take one treatment alone, or receive standard chemotherapy every 3 weeks. You will have regular clinic visits for blood tests, scans, and check-ins to monitor how the treatment is working and watch for side effects.
AI-generated summary from trial data · Aug 30, 2026 · Not medical advice
United States